MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
AcelRx Pharmaceuticals Retained Earnings 2011-2026 | ACRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -472 M | -457 M | -444 M | -426 M | -474 M | -438 M | -398 M | -345 M | -298 M | -246 M | -203 M | -179 M | -145 M | -122 M | -88.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -88.7 M | -474 M | -316 M |
Quarterly Retained Earnings AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -468 M | -463 M | -460 M | -457 M | -455 M | -452 M | -448 M | -444 M | -440 M | -438 M | -434 M | -426 M | -418 M | -412 M | -482 M | -474 M | -466 M | -457 M | -447 M | -438 M | -438 M | -438 M | -438 M | -398 M | -398 M | -398 M | -398 M | -345 M | -345 M | -345 M | -345 M | -298 M | -298 M | -298 M | -298 M | -246 M | -246 M | -246 M | -246 M | -203 M | -203 M | -203 M | -203 M | -179 M | -179 M | -179 M | -179 M | -145 M | -145 M | -145 M | -145 M | -122 M | -122 M | -122 M | -122 M | -88.7 M | -88.7 M | -88.7 M | -88.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -88.7 M | -482 M | -312 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M |  USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Cronos Group
CRON
|
1.06 B | - | - | $ 1.37 B |  Canada |
 |
Harrow Health
HROW
|
-157 M | - | - | $ 1.49 B | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 25.25 | 2.27 % | $ 1.17 B | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | - | - | $ 64.4 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 1.23 | 0.82 % | $ 1.53 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Tilray
TLRY
|
-2.42 B | $ 5.72 | -3.14 % | $ 3.53 B | Canada |
 |
Jupiter Wellness
JUPW
|
-183 M | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.6 | 1.45 % | $ 2.04 B | Canada |
 |
Solid Biosciences
SLDB
|
-958 M | - | - | $ 612 M | USA |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.1 | - | $ 118 M | Canada |
 |
Aurora Cannabis
ACB
|
-3.59 B | - | - | $ 86.3 M | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | - | - | $ 402 M | Canada |
 |
Evolus
EOLS
|
-661 M | - | - | $ 416 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.42 | -0.35 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-295 M | - | - | $ 314 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | - | - | $ 464 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | - | - | $ 340 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-353 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-182 M | $ 0.82 | -4.78 % | $ 3.54 M | USA |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-703 M | - | - | $ 142 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | - | - | $ 294 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 0.96 | -2.38 % | $ 47.9 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
5.18 B | - | - | $ 18.7 B | USA |
 |
Zomedica Corp.
ZOM
|
-300 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-403 M | $ 0.86 | -3.81 % | $ 30.9 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-47.2 M | - | - | $ 2.23 M |  China |
 |
TherapeuticsMD
TXMD
|
-952 M | - | - | $ 23.5 M | USA |